339 related articles for article (PubMed ID: 36868569)
21. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.
Liu Y; Wang J; Wu J; Yang Q; Zeng Y; Wu D; Tian C; Hu Y; Gu F; Li C; Zhang K; Liu L
Technol Cancer Res Treat; 2021; 20():1533033821997819. PubMed ID: 33715525
[TBL] [Abstract][Full Text] [Related]
23. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
[TBL] [Abstract][Full Text] [Related]
24. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
25. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Yang H; He D; Wang F; Deng Q; Xie Z
Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
27. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
28. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
Akhave N; Zhang J; Bayley E; Frank M; Chiou SH; Behrens C; Chen R; Hu X; Parra ER; Lee WC; Swisher S; Solis L; Weissferdt A; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Heymach JV; Lee JJ; Wistuba II; Andrew Futreal P; Zhang J; Fujimoto J; Reuben A
Lung Cancer; 2022 Oct; 172():19-28. PubMed ID: 35973335
[TBL] [Abstract][Full Text] [Related]
29. Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.
Qu R; Ye F; Hu S; Wang B; Qin S; Xiong J; Fu X; Li L; Cai Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3775-3788. PubMed ID: 35986758
[TBL] [Abstract][Full Text] [Related]
30.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
[TBL] [Abstract][Full Text] [Related]
32. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
Li M; Hou X; Sai K; Wu L; Chen J; Zhang B; Wang N; Wu L; Zheng H; Zhang J; Mou Y; Chen L
Oncoimmunology; 2022; 11(1):2059874. PubMed ID: 35402080
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of tumor immune microenvironment in malignant and metastatic change in LUAD is revealed by single-cell RNA sequencing.
Wang H; Han G; Chen J
Aging (Albany NY); 2023 Jun; 15(12):5339-5354. PubMed ID: 37335089
[TBL] [Abstract][Full Text] [Related]
34. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer.
Yang XR; Pi C; Zhang YC; Chen ZH; Zhang XC; Zhu DQ; Yang LL; Yin JC; Deng JY; Yang MY; Luo WC; Wu YL; Zhou Q
Mol Carcinog; 2023 Jul; 62(7):1001-1008. PubMed ID: 37067398
[TBL] [Abstract][Full Text] [Related]
36. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
37. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
38. Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations.
He D; Wang D; Lu P; Yang N; Xue Z; Zhu X; Zhang P; Fan G
Oncogene; 2021 Jan; 40(2):355-368. PubMed ID: 33144684
[TBL] [Abstract][Full Text] [Related]
39. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
